GC Green Cross Reports Record-High Q2 Sales Surpassing 500 Billion KRW

19.9% Increase Compared to the Same Period Last Year

GC Green Cross announced on August 1 that its consolidated sales for the second quarter of 2025 reached 500.3 billion KRW, marking a 19.9% increase compared to the same period last year. This is the first time that GC Green Cross's quarterly sales have surpassed 500 billion KRW.

GC Green Cross Headquarters, Yongin-si, Gyeonggi Province. GC Green Cross

During the same period, operating profit grew by 55.1% year-on-year to 27.4 billion KRW, while net profit reached 32.7 billion KRW.

The company explained that the record-high quarterly sales were driven by the global expansion of its key products. By business segment, GC Green Cross reported sales of 152 billion KRW from plasma derivatives, 102.9 billion KRW from vaccines, 106.1 billion KRW from prescription drugs, and 30.8 billion KRW from over-the-counter drugs and consumer healthcare.

In particular, the plasma derivatives segment saw a significant increase in sales of Aliglo. Aliglo achieved cumulative sales of 100 billion KRW in the United States as of July, just one year after its market launch.

A GC Green Cross representative stated, "Despite the economic uncertainties expected in the second half of the year, the strong performance of our core business segments is expected to continue."